IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

IQV has climbed 60.1% over the past six months, fueled by operational momentum and aggressive AI deployment across its pharma client base. The company posted 6% organic growth in Q2 2026, with its Research & Development Solutions bookings up 19.3% and a contract backlog standing at $34.2 billion.

IQVIA's AI strategy is gaining traction at scale: the company has deployed 294 AI agents spanning 90 use cases, with 19 of the top 20 global pharmaceutical companies now adopting its solutions. This breadth of penetration strengthens IQV's competitive moat in a sector where network effects and data integration drive pricing power.

The backlog figure—$34.2 billion—provides revenue visibility, while the double-digit bookings growth in R&DS suggests accelerating demand for contract research and data analytics services. AI adoption is transitioning from pilot to production, a shift that typically supports margin expansion as software-based services layer onto existing contracts.